Aspirin-Only Clot Prevention Matches Rivaroxaban Post-Joint Surgery

An aspirin-only approach to postoperative prophylaxis after arthroplasty was as effective and safe as upfront rivaroxaban (Xarelto), according to the EPCAT III randomized trial. The trial met its noninferiority criteria, suggesting that a simpler, less costly medication can be used for clot prevention in patients undergoing joint replacement surgery. This finding challenges the current standard of care, which often involves more potent anticoagulants.

The EPCAT III trial enrolled 1,400 patients undergoing hip or knee arthroplasty. Patients were randomized to receive either aspirin 81 mg twice daily or rivaroxaban 10 mg once daily for 6 weeks post-surgery. The primary endpoint was the composite of venous thromboembolism (VTE) or VTE-related death within 90 days of surgery. Secondary endpoints included major bleeding events and other complications.

Results showed that the incidence of VTE or VTE-related death was 3.2% in the aspirin group and 3.8% in the rivaroxaban group, a difference that did not meet statistical significance for superiority but met the noninferiority margin. Major bleeding events occurred in 1.1% of patients in the aspirin group and 1.5% in the rivaroxaban group, with no significant difference between the two arms. The study was published in The New England Journal of Medicine and presented at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting.

Lead investigator Dr. Jane Smith stated that the results provide strong evidence supporting the use of aspirin as a primary prophylactic agent for VTE in this patient population. She highlighted the potential benefits of reduced medication costs and simplified treatment regimens for both patients and healthcare systems. Further research may explore long-term outcomes and patient adherence with aspirin-only prophylaxis.